CAR-T therapy for recurrent ovarian cancer with B7H3
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests a personalized immune-cell treatment (fully human B7H3 CAR-T) for ovarian cancer that has come back or did not respond. It aims to see whether CAR-T can attack tumors that carry a target called B7H3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed ovarian cancer that has returned or not responded to first-line treatment
- Your tumor test shows B7H3 is positive in tissue or fluid from the abdomen
- You have measurable or scan-visible cancer (for example, a tumor at least 10 mm or enlarged lymph nodes)
- Your overall health is strong enough for study treatment (ECOG performance status 0–2) and you’re expected to live at least 12 weeks
- Your blood, liver, kidney, lung, and heart tests meet required minimum levels
- You can safely proceed with cell collection and treatment: you agree to consent, and you are not pregnant (and use reliable contraception if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
This trial tests a new treatment where your own immune cells are modified to attack ovarian cancer cells that have stopped responding to platinum chemotherapy. It's for people with recurrent ovarian cancer that hasn't gotten better with standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.